Gorlin syndrome is a rare inherited condition that predisposes a person to develop multiple basal cell carcinomas (a common type of skin cancer), jaw cysts, and a range of skeletal, neurological, and other abnormalities throughout life. It is caused by mutations in genes that control cell growth, and its effects can show up as early as infancy or as late as adulthood, depending on which gene is involved and which features appear first. The syndrome goes by several names in medical literature, including nevoid basal cell carcinoma syndrome and Gorlin-Goltz syndrome, and while it sounds alarming, many of its features are manageable with the right surveillance and treatment plan.
What Causes Gorlin Syndrome
Gorlin syndrome is driven by germline mutations in genes that are part of a cell-signaling system called the Hedgehog pathway. This pathway helps regulate how cells grow, divide, and specialize during development and throughout life. The most commonly affected gene is PTCH1, which normally acts as a brake on cell growth. When PTCH1 is mutated, that brake is weakened, and cells are more prone to forming tumors and cysts.1PubMed Central. Clinical Features and PTCH1 Expression in Gorlin-Goltz Syndrome: A Case Report
A smaller number of people with Gorlin syndrome carry mutations in a different gene called SUFU, which also participates in the Hedgehog pathway. This distinction is not just academic. The gene involved shapes which problems a person is most likely to face. People with SUFU mutations are significantly more likely to develop medulloblastoma (a brain tumor that appears in young children), meningiomas, and ovarian fibromas, but they are less likely to develop the jaw cysts that are so characteristic of PTCH1-related disease.2Journal of Medical Genetics. First evidence of genotype–phenotype correlations in Gorlin syndrome A third gene, PTCH2, has also been implicated in rare cases.3PubMed Central. Medulloblastoma in a toddler with Gorlin syndrome
The syndrome follows an autosomal dominant inheritance pattern, meaning a child only needs to inherit one copy of the mutated gene from one parent to be affected.4PubMed Central. Gorlin-Goltz syndrome New mutations also arise spontaneously in people with no family history, so a negative family history does not rule the condition out.
Basal Cell Carcinomas and Skin Findings
The defining feature of Gorlin syndrome for most patients is the development of multiple basal cell carcinomas. These skin cancers usually appear on the face, back, and chest, and they range from small flesh-colored bumps to larger ulcerating plaques. The number can vary enormously, from a handful over a lifetime to several thousand.5PubMed Central. Nevoid basal cell carcinoma syndrome (Gorlin syndrome) They tend to appear earlier than typical basal cell carcinomas in the general population, sometimes showing up in the teens or twenties rather than middle age.
Another telltale skin sign is palmoplantar pitting, which refers to tiny shallow depressions on the palms and soles. In one study of 30 patients, these pits were found in roughly three-quarters of the group.6PubMed Central. Gorlin Syndrome: A Comprehensive Evaluation of Skin Findings The pits are often overlooked because they are painless and small, but they serve as an important clinical clue, especially when a young person turns up with basal cell carcinomas and the diagnosis has not yet been made.
One common misconception is that these skin cancers must be caused by sun exposure, as is often the case with sporadic basal cell carcinomas. Research on Gorlin syndrome skin cells has shown that the tendency to develop these cancers is not simply a matter of UV damage. The cells appear to have normal DNA repair and survival after UV exposure. The cancer-proneness seems to stem more from cell-cycle alterations driven by the Hedgehog pathway defect, which is why basal cell carcinomas in Gorlin syndrome also appear on body areas that rarely see sunlight.7PubMed. Ultraviolet responses of Gorlin syndrome primary skin cells Sun protection is still sensible, but it will not prevent the syndrome’s skin cancers on its own.
Jaw Cysts
Odontogenic keratocysts of the jaw are another hallmark of Gorlin syndrome, especially in patients with PTCH1 mutations. These are fluid-filled sacs that develop in the jawbone, often discovered on dental X-rays before they cause symptoms. In syndromic patients they tend to be multiple, extensive, and prone to recurrence. If left untreated they can expand the bone and, in severe cases, lead to facial disfigurement.8PubMed Central. Multiple jaw cysts-unveiling the Gorlin-Goltz syndrome
These cysts often first appear in childhood or adolescence, and many patients undergo repeated surgeries over the years. A conservative two-stage surgical approach has been proposed for younger patients: first, the cyst is marsupialized (opened and drained) to shrink it, and then, after an average of about 10 months once the cyst has reduced in size, it is removed along with a thin layer of surrounding bone. In one group of young patients followed for five years, this approach preserved jaw structure and showed no recurrence.9PubMed. Two-stage treatment protocol of keratocystic odontogenic tumour in young patients with Gorlin-Goltz syndrome The goal is to avoid the kind of aggressive jaw surgery that would be disfiguring in a growing child, while still addressing the cyst completely.
Skeletal and Brain Calcification Findings
Gorlin syndrome produces a cluster of skeletal oddities that are often picked up incidentally on imaging. The most consistent radiological sign is calcification of the falx cerebri, a membrane that divides the two halves of the brain. In a study of 82 patients, this finding was present in about 65% overall, but the frequency climbed with age: roughly 37% of those under 20 had it, compared with about 79% of those over 40.10Genetics in Medicine. Radiological features in 82 patients with nevoid basal cell carcinoma (NBCC or Gorlin) syndrome This calcification is generally harmless and painless; its main value is as a diagnostic marker.
Bifid ribs, in which a rib is split or forked at one end, are another classic sign. They were found in about 26% of patients in the same study, most commonly affecting the third through fifth ribs. Some patients also had rib fusion or abnormal rib contours.11Genetics in Medicine. Radiological features in 82 patients with nevoid basal cell carcinoma (NBCC or Gorlin) syndrome Macrocephaly (a larger-than-average head) and other skull-shape variations, including sphenoid asymmetry and positional plagiocephaly, have also been documented on detailed CT imaging.12PubMed. Skeletal and cranio-facial signs in Gorlin syndrome from ancient Egypt to the modern age Like bifid ribs, these skeletal features rarely cause symptoms themselves but are useful in confirming a suspected diagnosis.
Medulloblastoma Risk in Children
The most serious concern in very young children with Gorlin syndrome is medulloblastoma, a brain tumor of the cerebellum. Population-based data suggest that roughly 3 to 5% of people with Gorlin syndrome develop medulloblastoma, and it tends to occur early, typically before age 5, often before age 3.13British Journal of Cancer. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma A cohort of 16 genetically confirmed patients with Gorlin syndrome and medulloblastoma showed ages at diagnosis ranging from under 1 year to about 3.4 years, with most tumors being of the desmoplastic or extensive nodularity subtypes and all showing Hedgehog pathway activation.14PubMed Central. Defining the Spectrum, Treatment and Outcome of Patients With Genetically Confirmed Gorlin Syndrome From the HIT-MED Cohort
The risk is not evenly distributed across all Gorlin patients. Those with SUFU mutations face a far higher likelihood of medulloblastoma than those with PTCH1 mutations. In one study, each family with a SUFU mutation included a case of medulloblastoma, while only about 1.7% of 115 individuals with PTCH1 mutations developed the tumor.15PubMed. Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations This distinction has direct implications for screening, as discussed below.
Other Tumors and Internal Findings
Beyond basal cell carcinomas and medulloblastoma, Gorlin syndrome predisposes to several other tumors. Ovarian fibromas, benign growths on one or both ovaries, have been reported in affected women and can sometimes be the first or even the sole presenting feature of the syndrome.16PubMed Central. Bilateral ovarian fibromas as the sole manifestation of Gorlin syndrome in a 22-year-old woman Cardiac fibromas, rare benign heart tumors, are another recognized association. They can occasionally cause arrhythmias, though they sometimes go undetected for years.17PubMed Central. Cardiac Fibroma with Asymptomatic Ventricular Arrhythmia in an Adolescent with Gorlin’s Syndrome Meningiomas, slow-growing tumors of the brain’s lining, are more common in SUFU carriers than in those with PTCH1 mutations.18Journal of Medical Genetics. First evidence of genotype–phenotype correlations in Gorlin syndrome
Facial dysmorphism is part of the syndrome’s description and can include macrocephaly, a broad nasal bridge, and, less commonly, cleft lip or palate and eye anomalies.19PubMed Central. Nevoid basal cell carcinoma syndrome (Gorlin syndrome) These features vary widely in severity. Some people with the syndrome look entirely unremarkable to a casual observer, while others have features that a trained clinician would recognize.
Eye Findings
Ophthalmological examination in Gorlin syndrome patients turns up a range of findings that often go unnoticed. A study of the eye features in a group of patients found strabismus (misaligned eyes) in 63%, epiretinal membranes in 36%, and myelinated optic nerve fiber layers in 36%. More widely cited findings such as hypertelorism (widely spaced eyes) were present in about 46%, congenital cataracts in 18%, and colobomas (gaps in eye structures) and nystagmus each in about 9%.20PubMed Central. Ocular manifestations in Gorlin-Goltz syndrome The high rate of strabismus in particular argues for early ophthalmological evaluation in children diagnosed with the syndrome, since untreated strabismus can affect vision development.
Why Radiation Is a Special Concern
People with Gorlin syndrome have heightened sensitivity to ionizing radiation, and this has major practical consequences. Radiation therapy, which is standard treatment for many cancers, has traditionally been contraindicated in Gorlin patients because it can trigger the development of new basal cell carcinomas in the irradiated skin.21PubMed Central. Successful Radiotherapy for Metastatic Basal Cell Carcinoma to the Parotid Gland in a Patient With Gorlin-Goltz Syndrome This is a particular concern when treating young children who develop medulloblastoma, since cranial radiation could seed dozens or hundreds of skin cancers on the scalp and face in the years that follow.22Handbook of Clinical Neurology. Basal cell nevus syndrome or Gorlin syndrome
The picture is not entirely black-and-white, however. Isolated case reports describe adult Gorlin patients who received radiotherapy for specific tumors and did not develop new cancers in the irradiated field after several years of follow-up.23PubMed. Radiotherapy in Gorlin Syndrome: Can It Be Safe and Effective in Adult Patients? These are exceptions, not the rule, and decisions about radiation in Gorlin patients are made on a case-by-case basis with careful weighing of alternatives. The general principle remains: avoid ionizing radiation when other options exist. This extends beyond cancer treatment to diagnostic imaging. Unnecessary CT scans and repeated plain X-rays should be minimized, and MRI is preferred when imaging is needed.
Hedgehog Inhibitor Drugs
The fact that Gorlin syndrome is driven by overactivity of the Hedgehog pathway has opened the door to targeted drug therapy. Two oral medications, vismodegib and sonidegib, directly block a protein in the Hedgehog signaling chain and are approved for advanced or recurrent basal cell carcinomas. For Gorlin patients, these drugs can be transformative. In one case series, sustained hedgehog inhibitor treatment reduced the average number of new basal cell cancers from about 28 before treatment to roughly 1 to 2 during treatment, and all patients achieved complete remission of existing tumors.24PubMed Central. Sustained Suppression of Gorlin Syndrome-Associated Basal Cell Carcinomas with Vismodegib or Sonidegib: A Case Series
Side effects are a significant limitation. Muscle cramps, hair loss, taste changes, and fatigue are common, and many patients struggle to stay on therapy long-term. Retrospective data suggest sonidegib may be better tolerated than vismodegib in some individuals, with comparable or superior efficacy.25PubMed Central. Gorlin Syndrome-Associated Basal Cell Carcinomas Treated with Vismodegib or Sonidegib: A Retrospective Study Patients who cannot tolerate vismodegib may successfully switch to sonidegib and achieve a complete response.26PubMed Central. Tolerance of sonidegib after intolerance of vismodegib-Experience in two patients with nevoid basal cell carcinoma syndrome (Gorlin syndrome) Adjusting the dosing schedule, such as taking the drug on alternate days or in cycles, has also helped improve tolerability without obviously sacrificing effectiveness.
These drugs are not a cure. When patients stop taking them, new basal cell carcinomas tend to reappear. The current approach for many Gorlin patients is long-term suppressive therapy, similar in concept to how some chronic conditions are managed with ongoing medication. Surgery remains the mainstay for individual tumors, especially isolated or large lesions, but for people developing dozens of new lesions a year, hedgehog inhibitors offer a meaningful reduction in surgical burden.
Surveillance Recommendations Based on Genotype
Because PTCH1 and SUFU mutations lead to different risk profiles, surveillance guidelines are increasingly tailored to the specific gene involved. An international working group has published recommendations that reflect these differences:27PubMed Central. Current recommendations for cancer surveillance in Gorlin syndrome
- Skin checks: Dermatologic examination should start around age 10 for people with PTCH1 mutations and around age 20 for those with SUFU mutations, since basal cell carcinomas are less of a concern in SUFU carriers.
- Jaw cyst screening: Dental examination should begin at age 2, with annual panoramic jaw X-rays starting around age 8. This applies primarily to PTCH1 carriers, who face the highest cyst burden.
- Brain MRI for medulloblastoma: Repeated brain MRI from birth to age 5 is recommended for children with SUFU mutations, given their much higher risk. This is not routinely recommended for PTCH1 carriers, in whom medulloblastoma is rare.
- Brain MRI for meningiomas: Offered to both PTCH1 and SUFU carriers, typically starting later in life.
- Pelvic ultrasound: Screening for ovarian fibromas is recommended for women with either mutation type.
Genetic testing to identify the specific mutation is therefore not just a formality. It shapes how aggressively and how early various screenings should begin, and it gives families a clearer picture of which complications to watch for.
How Gorlin Syndrome Gets Diagnosed
Diagnosis relies on a combination of clinical features and genetic testing. Traditionally, clinicians have used a set of major and minor criteria. Major criteria include multiple basal cell carcinomas (or one appearing before age 20), odontogenic keratocysts confirmed on histology, palmoplantar pitting, calcification of the falx cerebri, a first-degree relative with the syndrome, and medulloblastoma. Minor criteria include skeletal anomalies such as bifid ribs, macrocephaly, and various other findings. Meeting two major criteria, or one major and two minor, has been the standard diagnostic threshold.28PubMed Central. Nevoid basal cell carcinoma syndrome (Gorlin syndrome): a case report
In practice, many patients are diagnosed late. A young adult who goes to a dermatologist for what seems like a routine basal cell carcinoma might not get the connection made until they develop a second or third one. A dentist discovering a jaw cyst may not think of the syndrome unless the patient has other features. The diagnosis tends to click when someone puts together findings from multiple specialties. This is one reason genetic testing has become so valuable: it can confirm the diagnosis early, often before the full clinical picture has developed, and it can identify at-risk family members who should be screened.
Living with Gorlin Syndrome on a Practical Level
Day-to-day life with Gorlin syndrome involves an unusually high volume of medical appointments across multiple specialties: dermatology, oral surgery, ophthalmology, and, for some, oncology and cardiology. The surgical burden alone can be substantial. Patients who develop many basal cell carcinomas over the years may accumulate dozens of procedures, and jaw cyst recurrences can mean repeated oral surgeries during adolescence and young adulthood. The cosmetic impact of facial scarring from multiple surgeries and from the tumors themselves affects self-image, and the psychological toll of living with a condition that keeps producing new growths should not be underestimated.
For parents of a child newly diagnosed with Gorlin syndrome, the most pressing concern is usually medulloblastoma risk, particularly if the child carries a SUFU mutation. The reassuring side of the evidence is that medulloblastomas in Gorlin syndrome tend to be of the desmoplastic or extensively nodular subtypes, which generally carry a better prognosis than other medulloblastoma variants. The challenge is that standard treatment often involves radiation, which is precisely what these patients need to avoid. Treatment decisions require specialized centers experienced with the syndrome.
Adults with Gorlin syndrome often find that hedgehog inhibitor therapy, when tolerated, changes the rhythm of their disease management. Instead of a steady stream of surgical excisions, they can shift to periodic dermatology checks with fewer new lesions appearing. But the side effects mean the drugs are not right for everyone, and ongoing dialogue between patient and specialist about dosing and drug holidays is part of the process. The condition is lifelong, but with appropriate surveillance and a medical team familiar with its quirks, most people with Gorlin syndrome live a normal lifespan and maintain a good level of functioning.